AstraZeneca

The Alliance for Regenerative Medicine Appoints Rita Johnson-Greene as Chief Operating Officer

Retrieved on: 
Tuesday, March 21, 2023
Spark Therapeutics, University, Bluebird bio, QTC, Wharton School of the University of Pennsylvania, ARM, Electrical engineering, MBA, Medicine, Black, Drexel University, AstraZeneca, Regenerative medicine, Sales, Growth, Therapy, Electricity, DSM-IV codes, Pharmaceutical industry, Fine chemical

Ms. Johnson-Greene will be responsible for ARM’s strategic initiatives to build the organization’s membership, events business, and ongoing geographic expansion. She will oversee several functions­ -- including membership, events, finance, and people and culture -- and guide the execution of the organization’s major priorities. Ms. Johnson-Greene will also be responsible for ARM’s GROW Internship Program, which introduces Black students to the cell and gene therapy sector.

Key Points: 
  • Washington, D.C., March 21, 2023 (GLOBE NEWSWIRE) -- The Alliance for Regenerative Medicine (ARM), the leading international advocacy organization representing the engineered cell therapy and genetic medicines sector, announced the appointment of Rita Johnson-Greene as Chief Operating Officer, effective April 7.
  • Ms. Johnson-Greene will be responsible for ARM’s strategic initiatives to build the organization’s membership, events business, and ongoing geographic expansion.
  • Ms. Johnson-Greene will also be responsible for ARM’s GROW Internship Program, which introduces Black students to the cell and gene therapy sector.
  • “I am honored to serve as ARM’s Chief Operating Officer at such a momentous time for the cell and gene therapy sector,” said Ms. Johnson-Greene.

Mira Murati, CTO of OpenAI, Joins Unlearn.AI's Board of Directors

Retrieved on: 
Tuesday, March 21, 2023
Doctor of Philosophy, Tesla, Inc., ChatGPT, Model, Leap Motion, Research, Medicine, OpenAI, AstraZeneca, Tesla Model X, Patient, SAN, DALL-E, Artificial intelligence, Insight Partners, Medical device, Management, Unlearn

SAN FRANCISCO, March 21, 2023 /PRNewswire/ -- Unlearn®, a pioneering technology company using AI-generated digital twins of individual patients to revolutionize medical research, has appointed artificial intelligence (AI) luminary Mira Murati to its Board of Directors.

Key Points: 
  • SAN FRANCISCO, March 21, 2023 /PRNewswire/ -- Unlearn®, a pioneering technology company using AI-generated digital twins of individual patients to revolutionize medical research, has appointed artificial intelligence (AI) luminary Mira Murati to its Board of Directors.
  • As Chief Technology Officer of OpenAI, Ms. Murati leads research and product development teams for groundbreaking applications including DALL-E and ChatGPT.
  • "I'm incredibly excited to have Mira join the Unlearn team.
  • Unlearn's founding team worked with Mira at Leap Motion, so it feels a bit like we're putting the band back together.

AION Labs, In Continued Partnership with BioMed X, Launches First 2023 Global Call for Applications: Developing Molecular Glues

Retrieved on: 
Tuesday, March 21, 2023
Amazon Web Services, 3D, Research, AstraZeneca, Proteomics, AION, Protein, BioMed Central, Invention, Merck, AI, AWS, Pharmaceutical industry, Video game, Teva, Pfizer

REHOVOT, Israel and HEIDELBERG, Germany, March 21, 2023 /PRNewswire/ --  AION Labs, a first-of-its-kind innovation lab spearheading the adoption of AI technologies and computational science to solve therapeutic challenges, and German independent research institute BioMed X, announced today the launch of its first 2023 global call for applications to identify technological and biomedical scientists and inventors to form a new startup at AION Labs' headquarters in Rehovot, Israel.

Key Points: 
  • AION Labs' fifth startup will focus on the development of an AI platform that identifies naturally occurring protein of interest-E3 interacting pairs that work together in specific parts of the body under specific conditions.
  • It is also looking to model the 3D structure of the interacting complex to enable small molecule design.
  • As part of the online application procedure, interested candidates are requested to submit a competitive project proposal via the BioMed X Career Space at https://career.bio.mx/call/2023-AIL-C05 before May 7, 2023.
  • Further details about this call for application can be found on the AION Labs website: www.aionlabs.com .

Wugen Announces CEO Transition

Retrieved on: 
Tuesday, March 21, 2023
Biotechnology, Professional Services, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Science, Clinical Trials, Finance, University, Wyeth, University of Madras, COVID-19, Cancer, Case Western Reserve University, Bristol Myers Squibb, Biopharmaceutical, AstraZeneca, Acute myeloid leukemia, Chemistry, AML, Acquisition, Patient, Growth, Therapy, Pharmaceutical industry

Dr. Srinivasan succeeds Dan Kemp, Ph.D., who has stepped down from his CEO role and the Board of Directors to pursue other opportunities.

Key Points: 
  • Dr. Srinivasan succeeds Dan Kemp, Ph.D., who has stepped down from his CEO role and the Board of Directors to pursue other opportunities.
  • Under his leadership, the company will be well-positioned to advance our differentiated platform of memory NK and allogeneic CAR-T therapies for patients,” said Natalie Mount, Ph.D., Chair of the Board of Directors at Wugen.
  • “Wugen has made incredible strides advancing treatments for cancer patients.
  • I look forward to working with Wugen’s talented team as CEO and to continue to execute on our lead clinical-assets, WU-NK-101 and WU-CART-007.

PHARMACEUTICS INTERNATIONAL ONBOARDS NEW LEADERSHIP TEAM TO DRIVE QUALITY, OPERATIONAL IMPROVEMENTS, AND GROWTH

Retrieved on: 
Monday, March 20, 2023
Online, Vaccine, GMP, Human resources, AstraZeneca, Employment, General counsel, Asepsis, Culture, Head, Business operations, EVP, Abbott Laboratories, ISO, Valley, Business, Risk management, Olympus, PII, Thermo Fisher Scientific, Catalent, History, Assistant, Colorado Technical University, CDMO, Acquisition, Project management, Patient, Supply chain, HUNT, Getinge, ICU Medical, CFO, Supply, Grand River Aseptic Manufacturing, Indoxacarb, Management, Fine chemical, Pharmaceutical industry, MD, Sanofi

For over twenty-five years, the company has been providing technical and regulatory capabilities and Pharmaceutics Know-How™.

Key Points: 
  • For over twenty-five years, the company has been providing technical and regulatory capabilities and Pharmaceutics Know-How™.
  • Under Fowlers’ leadership, Pii will focus on the highest level of customer service.
  • Supporting Devan in his expanded role is Sara Frederick, who has joined Pii as Senior Director of Business Operations.
  • He has worked in many HR leadership roles in the medical technology space including Olympus and Thermo Fisher Scientific.

NewHydrogen Names Steven Hill as Vice President

Retrieved on: 
Monday, March 20, 2023
University, Solid oxide electrolyzer cell, Engineering, Marketing, Schering-Plough, IE Business School, Platinum, Research, AstraZeneca, Technology management, Associate, Business administration, Investment, Daiichi Sankyo, OTC, Iridium, Master of Business Administration, UCLA, Hill, Utah Valley University, Fine chemical, Management, Science, Aviation, Organon

SANTA CLARITA, Calif., March 20, 2023 (GLOBE NEWSWIRE) -- NewHydrogen, Inc. (OTC:NEWH), the developer of a breakthrough technology to produce low-cost green hydrogen, today announced that Steven Hill will serve as Vice President and member of the company’s board of directors, effective immediately. Hill is an accomplished sales executive with over 20 years of experience in the biopharmaceutical industry.

Key Points: 
  • SANTA CLARITA, Calif., March 20, 2023 (GLOBE NEWSWIRE) -- NewHydrogen, Inc. (OTC:NEWH), the developer of a breakthrough technology to produce low-cost green hydrogen, today announced that Steven Hill will serve as Vice President and member of the company’s board of directors, effective immediately.
  • Hill brings to NewHydrogen extensive experience and business knowledge gained from working in the pharmaceutical industry.
  • Hill also served as a Managing Member of Hill Investments, LLC, a real estate investment and design group during which time Mr. Hill consulted on property development and managed real estate investments.
  • “We are excited to welcome Steve to NewHydrogen, and expect that he will immediately strengthen our management team,” said Dr. David Lee, CEO of NewHydrogen.

Transgene: 2022 Full-year Results and Business Update

Retrieved on: 
Thursday, March 16, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, MSD, Progression-free survival, Cancer, Lung cancer, Virus, DNA, Vaccine, NCT, Euronext Paris, Conditional sentence, Pembrolizumab, AstraZeneca, Potyvirus, Neck, PFS, Neoplasm, Head, Death, Phase, IDMC, Patient, Toxicity, Merck & Co., Safety, Clinical trial, IV, Part, Circulating tumor DNA, Merck, PARP, Pharmaceutical industry, TG4050, Transgene

Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today publishes its financial results for 2022 and provides an update on its product pipeline.

Key Points: 
  • Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today publishes its financial results for 2022 and provides an update on its product pipeline.
  • I am confident that Transgene is at the forefront of helping to realize the potential of these exciting treatment modalities.
  • Transgene anticipates the last patient to be randomized in the trial in the first half of 2024, and final results to be communicated in 2024.
  • A clinical collaboration and supply agreement for KEYTRUDA® (pembrolizumab) was signed with MSD (Merck & Co) at the end of June 2022.

1 in 3 pemphigoid patients not well-managed on current treatments (MARKETVUE® REPORT)

Retrieved on: 
Thursday, March 16, 2023
Physician, Risk, AstraZeneca, Neonatal Fc receptor, Infection, Death, Patient, Steroid, Inflammation, Disease, Clinical trial, BP, REACH, Pharmaceutical industry

NEWTON, Mass., March 16, 2023 /PRNewswire/ -- Bullous pemphigoid (BP) is a rare, autoimmune, blistering disease for which there are no approved therapies. BP is associated with significant morbidities such as:

Key Points: 
  • Several companies including argenx, Sanofi/Regeneron, and AstraZeneca are seeking to improve Bullous Pemphigoid standard of care by pursuing label expansions for their existing antibody-based therapies.
  • NEWTON, Mass., March 16, 2023 /PRNewswire/ -- Bullous pemphigoid (BP) is a rare, autoimmune, blistering disease for which there are no approved therapies.
  • BP is associated with significant morbidities such as:
    In the absence of approved treatments, physicians utilize oral corticosteroids as first-line treatment to quickly eliminate pruritus and stop further blistering in the acute phase of BP.
  • I think there's enough in the pipeline that something will hopefully get an on-label indication, and that'll improve accessibility for patients to these treatments.

Lung Cancer Research Foundation Announces New Research Collaboration with Daiichi Sankyo and AstraZeneca

Retrieved on: 
Thursday, March 16, 2023
Research, Lung cancer, Spacecraft, HER2, AstraZeneca, Biomarker, Patient, ADC, Cytostasis, Woman, ET, Disease, NSCLC, Daiichi Sankyo, Doctor of Philosophy, Cancer, Recurrence, Pharmaceutical industry

NEW YORK, March 16, 2023 /PRNewswire/ -- The Lung Cancer Research Foundation (LCRF) today announced a collaboration with Daiichi Sankyo and AstraZeneca to fund up to three research grants focused on antibody drug conjugates (ADCs) to improve outcomes for people with lung cancer. Applications for these grants are being accepted through May 31, 2023.

Key Points: 
  • NEW YORK, March 16, 2023 /PRNewswire/ -- The Lung Cancer Research Foundation (LCRF) today announced a collaboration with Daiichi Sankyo and AstraZeneca to fund up to three research grants focused on antibody drug conjugates (ADCs) to improve outcomes for people with lung cancer.
  • This collaboration seeks to support research to study HER2 directed and TROP2 directed ADCs including mechanism of action, biomarkers, and resistance mechanisms.
  • "LCRF is honored to continue its long legacy of identifying and supporting outstanding lung cancer research projects over the years.
  • "The specific focus of this grant program is to further study ADCs and how they might be applied to lung cancer treatment.

MediWound Announces the Appointment of Hani Luxenburg as Chief Financial Officer

Retrieved on: 
Thursday, March 16, 2023
University of Haifa, Regeneration, Bachelor of Laws, AstraZeneca, Bromelain (pharmacology), IDC, Ernst & Young, Israel Bar Association, Growth, Reichman University, University, Management, Economics

YAVNE, Israel, March 16, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company specializing in next-generation biotherapeutic solutions for tissue repair and regeneration, is pleased to announce the appointment of Ms. Hani Luxenburg as its new Chief Financial Officer, effective May 14, 2023.

Key Points: 
  • YAVNE, Israel, March 16, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company specializing in next-generation biotherapeutic solutions for tissue repair and regeneration, is pleased to announce the appointment of Ms. Hani Luxenburg as its new Chief Financial Officer, effective May 14, 2023.
  • Ms. Luxenburg will replace Mr. Boaz Gur-Lavie, who has served as MediWound’s Chief Financial Officer for the past four years.
  • With over 20 years of progressive leadership experience managing financial and accounting operations, Ms. Luxenburg joins MediWound with a proven track record delivering positive business growth and profitable financial results in the technology and life sciences sectors.
  • Most recently, Ms. Luxenburg served as Chief Financial Officer at BIRD Aerosystems.